Pharmacokinetics, safety, and tolerability of an oxfendazole tablet formulation: a phase 1, randomized, placebo-controlled trial in healthy African volunteers. (2026)

Peer-Reviewed Study · Jongo S, Ackermann E, Nyaulingo G, Mbaraka H, Reus E, Cicconi S, Saxena M, Kassim K, Tumbo A, Rashid MA, Robinson S, Louis M, Satam V, Rocha FBDS, Scandale I, Assmus F, Keiser J, Specht S · 2026

Jongo S et al., 2026: Phase 1 randomized placebo-controlled trial of an oxfendazole tablet in 30 healthy African volunteers, giving 100 mg or 400 mg single doses or 400 mg daily for five days. Median half-life was 11.6-13.9 h and no adverse events were reported.

The median elimination half-life ranged from 11.6 to 13.9 h and was consistent across cohorts.

Jongo S et al., 2026: Phase 1 randomized placebo-controlled trial of an oxfendazole tablet in 30 healthy African volunteers, giving 100 mg or 400 mg single doses or 400 mg daily for five days. Median half-life was 11.6-13.9 h and no adverse events were reported. Phase 1, randomized, placebo-controlled bioavailability trial; N=30 healthy adults, randomized 8:2 oxfendazole:placebo per cohort; Tanzania (Bagamoyo); oxfendazole 100 mg or 400 mg single dose, or 400 mg daily for 5 days, immediate-release tablet; NCT04920292. Funder: Horizon 2020 grant 815628. Declared conflicts: authors declare no conflict of interest. Product: oxfendazole tablet, formulation developed by the trial consortium. Comparator: placebo. Human oxfendazole data, not fenbendazole; it is the most recent human PK for the metabolite. Study type: randomized trial.